Cargando…

A third dose of the BNT162b2 mRNA vaccine sufficiently improves the neutralizing activity against SARS-CoV-2 variants in liver transplant recipients

INTRODUCTION: We examined the neutralizing antibody production efficiency of the second and third severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine doses (2(nd)- and 3(rd)-dose) and neutralizing activity on mutant strains, including, the Ancestral, Beta and Omicron strains using g...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomiyama, Takahiro, Suzuki, Rigel, Harada, Noboru, Tamura, Tomokazu, Toshida, Katsuya, Kosai-Fujimoto, Yukiko-, Tomino, Takahiro, Yoshiya, Shohei, Nagao, Yoshihiro, Takeishi, Kazuki, Itoh, Shinji, Kobayashi, Nobuhiro, Ito, Hayato, Yoshio, Sachiyo, Kanto, Tatsuya, Yoshizumi, Tomoharu, Fukuhara, Takasuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229048/
https://www.ncbi.nlm.nih.gov/pubmed/37260700
http://dx.doi.org/10.3389/fcimb.2023.1197349
_version_ 1785051152703815680
author Tomiyama, Takahiro
Suzuki, Rigel
Harada, Noboru
Tamura, Tomokazu
Toshida, Katsuya
Kosai-Fujimoto, Yukiko-
Tomino, Takahiro
Yoshiya, Shohei
Nagao, Yoshihiro
Takeishi, Kazuki
Itoh, Shinji
Kobayashi, Nobuhiro
Ito, Hayato
Yoshio, Sachiyo
Kanto, Tatsuya
Yoshizumi, Tomoharu
Fukuhara, Takasuke
author_facet Tomiyama, Takahiro
Suzuki, Rigel
Harada, Noboru
Tamura, Tomokazu
Toshida, Katsuya
Kosai-Fujimoto, Yukiko-
Tomino, Takahiro
Yoshiya, Shohei
Nagao, Yoshihiro
Takeishi, Kazuki
Itoh, Shinji
Kobayashi, Nobuhiro
Ito, Hayato
Yoshio, Sachiyo
Kanto, Tatsuya
Yoshizumi, Tomoharu
Fukuhara, Takasuke
author_sort Tomiyama, Takahiro
collection PubMed
description INTRODUCTION: We examined the neutralizing antibody production efficiency of the second and third severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine doses (2(nd)- and 3(rd)-dose) and neutralizing activity on mutant strains, including, the Ancestral, Beta and Omicron strains using green fluorescent protein-carrying recombinant SARS-CoV-2, in living-donor liver transplantation (LDLT) recipients. METHODS: The patients who were administered vaccines other than Pfizer- BioNTechBNT162b2 and who had coronavirus disease 2019 in this study period were excluded. We enrolled 154 LDLT recipients and 50 healthy controls. RESULT: The median time were 21 days (between 1(st) and 2(nd) vaccination) and 244 days (between 2(nd) and 3(rd) vaccination). The median neutralizing antibody titer after 2(nd)-dose was lower in LDLT recipients than in controls (0.46 vs 1.00, P<0.0001). All controls had SARS-CoV-2 neutralizing antibodies, whereas 39 LDLT recipients (25.3%) had no neutralizing antibodies after 2(nd)-dose; age at vaccination, presence of ascites, multiple immunosuppressive treatments, and mycophenolate mofetil treatment were significant risk factors for nonresponder. The neutralizing activities of recipient sera were approximately 3-fold and 5-fold lower than those of control sera against the Ancestral and Beta strains, respectively. The median antibody titer after 3(rd)-dose was not significantly different between recipients and controls (1.02 vs 1.22, p=0.0758); only 5% recipients was non-responder. The neutralizing activity after third dose to Omicron strains were enhanced and had no significant difference between two groups. CONCLUSION: Only the 2nd-dose was not sufficiently effective in recipients; however, 3rd-dose had sufficient neutralizing activity against the mutant strain and was as effective as that in healthy controls.
format Online
Article
Text
id pubmed-10229048
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102290482023-05-31 A third dose of the BNT162b2 mRNA vaccine sufficiently improves the neutralizing activity against SARS-CoV-2 variants in liver transplant recipients Tomiyama, Takahiro Suzuki, Rigel Harada, Noboru Tamura, Tomokazu Toshida, Katsuya Kosai-Fujimoto, Yukiko- Tomino, Takahiro Yoshiya, Shohei Nagao, Yoshihiro Takeishi, Kazuki Itoh, Shinji Kobayashi, Nobuhiro Ito, Hayato Yoshio, Sachiyo Kanto, Tatsuya Yoshizumi, Tomoharu Fukuhara, Takasuke Front Cell Infect Microbiol Cellular and Infection Microbiology INTRODUCTION: We examined the neutralizing antibody production efficiency of the second and third severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine doses (2(nd)- and 3(rd)-dose) and neutralizing activity on mutant strains, including, the Ancestral, Beta and Omicron strains using green fluorescent protein-carrying recombinant SARS-CoV-2, in living-donor liver transplantation (LDLT) recipients. METHODS: The patients who were administered vaccines other than Pfizer- BioNTechBNT162b2 and who had coronavirus disease 2019 in this study period were excluded. We enrolled 154 LDLT recipients and 50 healthy controls. RESULT: The median time were 21 days (between 1(st) and 2(nd) vaccination) and 244 days (between 2(nd) and 3(rd) vaccination). The median neutralizing antibody titer after 2(nd)-dose was lower in LDLT recipients than in controls (0.46 vs 1.00, P<0.0001). All controls had SARS-CoV-2 neutralizing antibodies, whereas 39 LDLT recipients (25.3%) had no neutralizing antibodies after 2(nd)-dose; age at vaccination, presence of ascites, multiple immunosuppressive treatments, and mycophenolate mofetil treatment were significant risk factors for nonresponder. The neutralizing activities of recipient sera were approximately 3-fold and 5-fold lower than those of control sera against the Ancestral and Beta strains, respectively. The median antibody titer after 3(rd)-dose was not significantly different between recipients and controls (1.02 vs 1.22, p=0.0758); only 5% recipients was non-responder. The neutralizing activity after third dose to Omicron strains were enhanced and had no significant difference between two groups. CONCLUSION: Only the 2nd-dose was not sufficiently effective in recipients; however, 3rd-dose had sufficient neutralizing activity against the mutant strain and was as effective as that in healthy controls. Frontiers Media S.A. 2023-05-16 /pmc/articles/PMC10229048/ /pubmed/37260700 http://dx.doi.org/10.3389/fcimb.2023.1197349 Text en Copyright © 2023 Tomiyama, Suzuki, Harada, Tamura, Toshida, Kosai-Fujimoto, Tomino, Yoshiya, Nagao, Takeishi, Itoh, Kobayashi, Ito, Yoshio, Kanto, Yoshizumi and Fukuhara https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Tomiyama, Takahiro
Suzuki, Rigel
Harada, Noboru
Tamura, Tomokazu
Toshida, Katsuya
Kosai-Fujimoto, Yukiko-
Tomino, Takahiro
Yoshiya, Shohei
Nagao, Yoshihiro
Takeishi, Kazuki
Itoh, Shinji
Kobayashi, Nobuhiro
Ito, Hayato
Yoshio, Sachiyo
Kanto, Tatsuya
Yoshizumi, Tomoharu
Fukuhara, Takasuke
A third dose of the BNT162b2 mRNA vaccine sufficiently improves the neutralizing activity against SARS-CoV-2 variants in liver transplant recipients
title A third dose of the BNT162b2 mRNA vaccine sufficiently improves the neutralizing activity against SARS-CoV-2 variants in liver transplant recipients
title_full A third dose of the BNT162b2 mRNA vaccine sufficiently improves the neutralizing activity against SARS-CoV-2 variants in liver transplant recipients
title_fullStr A third dose of the BNT162b2 mRNA vaccine sufficiently improves the neutralizing activity against SARS-CoV-2 variants in liver transplant recipients
title_full_unstemmed A third dose of the BNT162b2 mRNA vaccine sufficiently improves the neutralizing activity against SARS-CoV-2 variants in liver transplant recipients
title_short A third dose of the BNT162b2 mRNA vaccine sufficiently improves the neutralizing activity against SARS-CoV-2 variants in liver transplant recipients
title_sort third dose of the bnt162b2 mrna vaccine sufficiently improves the neutralizing activity against sars-cov-2 variants in liver transplant recipients
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229048/
https://www.ncbi.nlm.nih.gov/pubmed/37260700
http://dx.doi.org/10.3389/fcimb.2023.1197349
work_keys_str_mv AT tomiyamatakahiro athirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT suzukirigel athirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT haradanoboru athirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT tamuratomokazu athirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT toshidakatsuya athirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT kosaifujimotoyukiko athirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT tominotakahiro athirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT yoshiyashohei athirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT nagaoyoshihiro athirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT takeishikazuki athirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT itohshinji athirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT kobayashinobuhiro athirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT itohayato athirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT yoshiosachiyo athirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT kantotatsuya athirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT yoshizumitomoharu athirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT fukuharatakasuke athirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT tomiyamatakahiro thirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT suzukirigel thirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT haradanoboru thirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT tamuratomokazu thirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT toshidakatsuya thirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT kosaifujimotoyukiko thirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT tominotakahiro thirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT yoshiyashohei thirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT nagaoyoshihiro thirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT takeishikazuki thirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT itohshinji thirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT kobayashinobuhiro thirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT itohayato thirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT yoshiosachiyo thirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT kantotatsuya thirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT yoshizumitomoharu thirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients
AT fukuharatakasuke thirddoseofthebnt162b2mrnavaccinesufficientlyimprovestheneutralizingactivityagainstsarscov2variantsinlivertransplantrecipients